Patents

US 12384852 B2: Genetically modified NK-92 cells having a safety switch

Granted
2025-08-12
Filed
2021-11-18 application 17530211
Type
Utility · 20 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

Source: PVGPATDIS, file of 2026-04-10 (ipg250812.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
Institute for Cancer Research 70 patentsUS company or organizationPhiladelphia, PAINSTITUTE FOR CANCER RESEARCH Nonprofit EXACT high confidence: identical full name and statePVGPATDIS, file of 2026-04-10
ImmunityBio, Inc. 71 patentsUS company or organizationSan Diego, CAImmunityBio, Inc. Form D issuer EXACT high confidence: identical full name and state
IMMUNITYBIO, INC. Federal lobbying client EXACT high confidence: identical full name and state
IMMUNITYBIO, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Tien LeeSan Diego, CA13PVGPATDIS, file of 2026-04-10
Hans G. KlingemannSan Diego, CA45PVGPATDIS, file of 2026-04-10
Barry J. SimonSan Diego, CA18PVGPATDIS, file of 2026-04-10
Laurent H. BoisselSan Diego, CA35PVGPATDIS, file of 2026-04-10
Kerry S. CampbellWyncote, PA4PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
C07KPeptidesC07K16/2887PVGPATDIS, file of 2026-04-10
A61KPreparations for medical, dental or toiletry purposesA61K39/39558PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P35/00PVGPATDIS, file of 2026-04-10
C12NMicroorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture mediaC12N5/0646PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2024-03-12Name change
Change of name
NANTKWEST, INC. signed 2021-03-09IMMUNITYBIO, INC. SAN DIEGO, CA66801/776ECORSEXC, file of 2026-09-25
2024-03-12Assignment
Assignment of assignor's interest
SIMON, BARRY J. signed 2016-03-30
BOISSEL, LAURENT signed 2016-04-22
KLINGEMANN, HANS G. signed 2016-04-22
LEE, TIEN signed 2016-04-22
NANTKWEST, INC. CULVER CITY, CA66738/859ECORSEXC, file of 2026-09-25
2024-01-02Security interest Security interest
Security interest
IMMUNITYBIO, INC. signed 2023-12-29
NANTCELL, INC. signed 2023-12-29
RECEPTOME, INC. signed 2023-12-29
VBC HOLDINGS LLC signed 2023-12-29
ALTOR BIOSCIENCE, LLC signed 2023-12-29
ETUBICS CORPORATION signed 2023-12-29
IGDRASOL, INC. signed 2023-12-29
INFINITY SA LLC, AS PURCHASER AGENT NEW YORK, NY66179/74PASDL, file of 2026-10-15
2023-10-23Assignment
Assignment of assignor's interest
CAMPBELL, KERRY signed 2023-10-20INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER PHILADELPHIA, PA65304/975ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.